Man Group’s Avita Medical RCEL Stock Holding History

Man Group’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,688	Closed	-$333K	–	1741
2023 Q2	$335K	Buy	+19,688	New	+$289K	﹤0.01%	1694
2023 Q1	–	Sell	-21,513	Closed	-$229K	–	1829
2022 Q4	$142K	Buy	+21,513	New	+$129K	﹤0.01%	1840

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Man Group's RCEL Position: Q3 2023 in Review

Man Group sold out of Avita Medical (RCEL) in Q3 2023, closing a stake of 19,688 shares — an estimated $333K sold.

Man Group first reported a position in RCEL in Q4 2022 and held it in 2 quarters. The position peaked at $335K in Q2 2023. 80 funds tracked by Wall St. Rank hold RCEL as of Q3 2023.

Man Group reported no remaining Avita Medical position as of Q3 2023 after selling out during the quarter.
Man Group sold 19,688 Avita Medical shares in Q3 2023, an estimated $333K.
Man Group first reported a position in Avita Medical in Q4 2022 and held it in 2 quarters.
Man Group's Avita Medical position peaked at $335K in Q2 2023.
80 funds tracked by Wall St. Rank held Avita Medical as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.